


Claims

- 1 A compound of formula (I), a pharmaceutically acceptable salt, solvate or derivative thereof:



(I)

wherein X is N or CH;

R<sup>1</sup> is selected from hydrogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkenyl, C<sub>1-6</sub>alkoxy, halo, cyano, perfluoro C<sub>1-6</sub>alkyl, perfluoroC<sub>1-6</sub>alkoxy, -NR<sup>4</sup>R<sup>5</sup>, -(CH<sub>2</sub>)<sub>n</sub>NR<sup>4</sup>R<sup>5</sup>, -O(CH<sub>2</sub>)<sub>n</sub>OR<sup>6</sup>, -O(CH<sub>2</sub>)<sub>n</sub>NR<sup>4</sup>R<sup>5</sup>, -CONR<sup>4</sup>R<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>n</sub>NR<sup>4</sup>R<sup>5</sup>, -SO<sub>2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, -NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup> and -NR<sup>4</sup>COR<sup>6</sup>;

R<sup>2</sup> is hydrogen, C<sub>1-6</sub>alkyl, halo, cyano or perfluoroC<sub>1-6</sub>alkyl;

R<sup>3</sup> is hydrogen or halo;

R<sup>4</sup> and R<sup>5</sup> are independently hydrogen, C<sub>1-6</sub>alkyl or Het; or R<sup>4</sup> and R<sup>5</sup> together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7-membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be further substituted by one or more substituents selected from halo (such as fluoro, chloro, bromo), cyano, -CF<sub>3</sub>, hydroxy, -OCF<sub>3</sub>, C<sub>1-6</sub>alkyl and C<sub>1-6</sub>alkoxy;

R<sup>6</sup> is hydrogen or C<sub>1-6</sub>alkyl;

Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C<sub>1-6</sub>alkyl; and

n is 1-4.

- 2 A compound according to claim 1 wherein X is N.

- 3 A compound according to any preceding claim wherein  $R^1$  is  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halo, perfluoro $C_{1-6}$ alkoxy,  $-(CH_2)_nNR^4R^5$ ,  $-O(CH_2)_nNR^4R^5$ ,  $-CONR^4R^5$  or  $-SO_2R^6$ .
- 4 A compound according to any preceding claim wherein  $R^2$  is hydrogen,  $C_{1-6}$ alkyl, chloro or fluoro.
- 5 A compound according to any preceding claim wherein  $R^3$  is hydrogen or fluoro.
- 6 A compound according to any preceding claim wherein when X is N,  $R^2$  is methyl.
- 7 A compound according to any preceding claim wherein when X is N and  $R^2$  is methyl,  $R^3$  is hydrogen.
- 8 A compound according to any preceding claim wherein  $R^4$  and  $R^5$  are independently hydrogen,  $C_{1-6}$ alkyl or Het; or  $R^4$  and  $R^5$  together with the atom to which they are attached form a morpholine, piperidine, pyrrolidine, piperazine or N-methyl piperazine ring, each of which may be substituted by halo (such as fluoro, chloro, bromo), cyano,  $-CF_3$ , hydroxy,  $-OCF_3$ ,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkoxy.
- 9 A compound according to claim 1 wherein  
X is N;  
 $R^1$  is  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halo, perfluoro $C_{1-6}$ alkoxy,  $-(CH_2)_nNR^4R^5$ ,  $-O(CH_2)_nNR^4R^5$ ,  $-CONR^4R^5$  or  $-SO_2R^6$ ;  
 $R^2$  is hydrogen,  $C_{1-6}$ alkyl, chloro or fluoro;  
 $R^3$  is hydrogen or halo;  
 $R^4$  and  $R^5$  are independently hydrogen,  $C_{1-6}$ alkyl or Het; or  $R^4$  and  $R^5$  together with the atom to which they are attached form a morpholine, piperidine, pyrrolidine or piperazine or N-methyl piperazine ring, each of which may be substituted by halo (such as fluoro, chloro, bromo), cyano,  $-CF_3$ , hydroxy,  $-OCF_3$ ,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkoxy.  
 $R^6$  is hydrogen or  $C_{1-6}$ alkyl;

Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C<sub>1-6</sub>alkyl; and

n is 1-4.

- 10 A compound according to claim 1 selected from the list:  
 2-(4-methanesulfonylphenyl)-4-(5-(6-methyl)-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl)-pyridine (Example 1);  
 2-(4-methoxyphenyl)-4-(5-(6-methyl)-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl)-pyridine (Example 2);  
 dimethyl-[2-(4-{4-[5-(6-methyl)-pyridin-2-yl]-3H-[1,2,3]triazol-4-yl)-pyridin-2-yl]-phenoxy)-ethyl]-amine (Example 3);  
 4-{4-[5-(6-methyl-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl]-pyridin-2-yl}-benzyl)-morpholine (Example 4);  
 2-(4-ethylphenyl)-4-(5-(6-methyl-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl)-pyridine (Example 5);  
 4-{4-[5-(6-methyl-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl]-pyridin-2-yl}-N-(tetrahydro-pyran-4-yl)-benzamide (Example 6);  
 2-(4-chlorophenyl)-4-(5-(6-methyl)-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl)-pyridine (Example 7);  
 2-(4-trifluoromethoxyphenyl)-4-(5-(6-methyl)-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl)-pyridine (Example 8);  
 2-{4-(2-pyrrolidin-1-yl-ethoxy)-phenyl}-4-(5-(6-methyl)-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl)-pyridine (Example 9); and  
 2-(4-fluorophenyl)-4-(5-(6-methyl)-pyridin-2-yl)-3H-[1,2,3]triazol-4-yl)-pyridine (Example 10);  
 and pharmaceutically acceptable salts, solvates and derivatives thereof.
- 11 A pharmaceutical composition comprising a compound defined in any preceding claim and a pharmaceutically acceptable carrier or diluent.
- 12 The use of a compound defined in any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prophylaxis of a disorder mediated by the ALK5 receptor in mammals.

- 13     The use according to claim 12 wherein the disorder is selected from chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis, kidney fibrosis, liver fibrosis [for example, hepatitis B virus (HBV), hepatitis C virus (HCV)], alcohol induced hepatitis, retroperitoneal fibrosis, mesenteric fibrosis, haemochromatosis and primary biliary cirrhosis, endometriosis, keloids and restenosis.
- 14     The use according to claim 13 wherein the disorder is kidney fibrosis.
- 15     A compound defined in any one of claims 1 to 10 for use as a medicament.